 The primary efficacy endpoint in this study is to assess the effectiveness of JBM-TC4 for the prevention and treatment of acute radiation-induced dermatitis. The effectiveness will be determined by the recording of the radiation dermatitis severity scale for patients during each weekly study visit. Secondary efficacy endpoint include 1 Presence of moist desquamation and 2 redness at the radiation treated site at any visit. 3The worst pain related to dermatitis between baseline and follow-up visit at the radiotherapy site. 4 Quality of life and 5 safety evaluation assessment. At the final visit, each investigator will be ask to rate their patients responses to treatment. 